Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) major shareholder Group Gp Lp Column III sold 658,440 shares of Tenaya Therapeutics stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $0.62, for a total value of $408,232.80. Following the completion of the transaction, the insider directly owned 1,649,281 shares in the company, valued at $1,022,554.22. This represents a 28.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Major shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.
Group Gp Lp Column III also recently made the following trade(s):
- On Wednesday, February 25th, Group Gp Lp Column III sold 3,511,826 shares of Tenaya Therapeutics stock. The shares were sold at an average price of $0.56, for a total transaction of $1,966,622.56.
- On Wednesday, February 11th, Group Gp Lp Column III sold 4,056,573 shares of Tenaya Therapeutics stock. The stock was sold at an average price of $0.68, for a total transaction of $2,758,469.64.
- On Tuesday, February 10th, Group Gp Lp Column III sold 343,717 shares of Tenaya Therapeutics stock. The stock was sold at an average price of $0.82, for a total transaction of $281,847.94.
Tenaya Therapeutics Price Performance
TNYA stock opened at $0.61 on Friday. The firm has a market capitalization of $99.73 million, a P/E ratio of -0.78 and a beta of 3.18. Tenaya Therapeutics, Inc. has a 52-week low of $0.36 and a 52-week high of $2.35. The company's 50 day simple moving average is $0.72 and its 200-day simple moving average is $1.14.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the company. Savant Capital LLC acquired a new position in Tenaya Therapeutics in the second quarter worth approximately $52,000. CWM LLC grew its position in Tenaya Therapeutics by 25.2% in the second quarter. CWM LLC now owns 90,087 shares of the company's stock worth $55,000 after acquiring an additional 18,142 shares in the last quarter. Cerity Partners LLC grew its position in Tenaya Therapeutics by 403.5% in the second quarter. Cerity Partners LLC now owns 110,336 shares of the company's stock worth $67,000 after acquiring an additional 88,424 shares in the last quarter. Comerica Bank acquired a new position in shares of Tenaya Therapeutics during the 1st quarter worth $50,000. Finally, Scientech Research LLC bought a new position in shares of Tenaya Therapeutics during the 3rd quarter valued at $27,000. Hedge funds and other institutional investors own 90.54% of the company's stock.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on the company. HC Wainwright reduced their target price on Tenaya Therapeutics from $5.00 to $3.00 and set a "buy" rating for the company in a report on Friday, December 12th. Chardan Capital reduced their price objective on Tenaya Therapeutics from $9.00 to $8.00 and set a "buy" rating for the company in a research note on Friday, December 12th. Canaccord Genuity Group decreased their price objective on Tenaya Therapeutics from $6.00 to $5.00 and set a "buy" rating for the company in a research report on Thursday, December 18th. Morgan Stanley set a $2.00 target price on Tenaya Therapeutics in a report on Thursday, January 8th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Tenaya Therapeutics in a research report on Wednesday, January 21st. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $4.50.
Get Our Latest Report on Tenaya Therapeutics
Tenaya Therapeutics Company Profile
(
Get Free Report)
Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.
Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
